Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

• Status: Completed
• Trial end date: 2016-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research study is to determine if the combination of docetaxel, cisplatin, irinotecan and bevacizumab will help shrink metastatic esophageal or gastric cancer and how the cancer responds to this combination. Bevacizumab is a new drug that is believed to stop the formation of new blood vessels that carry nutrients to tumors. Bevacizumab is approved for use in metastatic colon and rectal cancer. Docetaxel, cisplatin and irinotecan are traditional chemotherapy agents that have been tested together in another clinical trial for esophageal and gastric cancer. It is hoped that adding bevacizumab to this regimen will make the treatment more effective.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Collaborators: Brigham and Women's Hospital; Genentech, Inc.; Massachusetts General Hospital
• Treatments: Bevacizumab; Camptothecin; Cisplatin; Docetaxel; Irinotecan

Criteria

Inclusion Criteria:

• Histologically confirmed, unresectable esophageal or gastric carcinoma (carcinoma=adenocarcinoma or squamous cell carcinoma)

• Measurable disease greater than or equal to 1 cm (longest diameter) by spiral computed tomography (CT) scan or 2 cm or greater by other radiographic technique

• Lesions must be measurable in at least one dimension

• Bone lesions, ascites, and effusions are not measurable

• 18 years of age or older

• ECOG performance status 0 or 1

• Life expectancy of at least 12 weeks

• Adequate bone marrow function

• Adequate renal function

• Adequate liver function

Exclusion Criteria:

• Prior chemotherapy (except as part of pre- or post-operative therapy, completed more than 1 year prior to start day of this protocol)

• History of severe hypersensitivity to bevacizumab, docetaxel, cisplatin, irinotecan, or drugs formulated with polysorbate 80

• Current, recent (within 4 weeks) or planned participation in an experimental drug study

• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, or anticipation of need for major surgical procedure during the course of the study

• Minor surgical procedures, such as fine needle aspirations, port-a-cath placement, or core biopsies within 7 days prior to Day 0 of study

• Myocardial infarction or stroke in past 6 months

• Blood pressure of > 150/100 mmHg

• Unstable angina

• New York Heart Association (NYHA) grade II or greater congestive heart failure

• Clinically significant peripheral vascular disease

• Persistent bleeding from primary tumor, while off anticoagulants, requiring repeated transfusions

• Evidence of bleeding diathesis or coagulopathy

• Uncontrolled serious medical or psychiatric illness

• Uncontrolled diarrhea

• Peripheral neuropathy > grade 1

• Clinically apparent central nervous system metastases or carcinomatous meningitis

• Other active malignancy other than non-melanoma skin cancer or in situ cervical carcinoma.

• Urine protein: creatinine ratio of 1.0 or greater at screening

• History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1

• Serious non-healing wound, ulcer, or bone fracture

• Pregnant or breast-feeding